Table 1.
Clinical features of SSc patients and control subjects involved in monocyte experiments.
| SSc (n = 11) | Controls (n = 20) | ||
|---|---|---|---|
| Age | Mean ± SD (years) | 54.2 ± 10.9 | 40.7 ± 12.9 |
| Range (years) | 37–69 | 18–55 | |
| Disease duration | Mean ± SD (years) | 5.7 ± 5.3 | |
| Range (years) | 1–16 | ||
| Number (%) | Number (%) | ||
| Race | Caucasian (male) | 2 (18.2) | 3 (15.0) |
| Caucasian (female) | 4 (36.4) | 7 (35.0) | |
| African-American (male) | 3 (27.3) | 2 (10.0) | |
| African-American (female) | 3 (27.3) | 8 (40.0) | |
| Smoking status | Smoker | 0 (0) | 1 (5.0) |
| Former smoker | 1 (9.1) | 1 (5.0) | |
| Diagnosis | Limited cutaneous | 6 (54.6) | |
| Diffuse cutaneous | 5 (45.5) | ||
| Overlap | 1 (9.1) | ||
| Symptoms | Pulmonary involvement (ILD) | 7 (63.6) | |
| Pulmonary hypertension | 1 (9.1) | ||
| Gastrointestinal involvement | 1 (9.1) | ||
| Cardiac involvement | 2 (18.2) | ||
| Renal involvement | 1 (9.1) | ||
| Raynaud phenomenon | 11 (100) | ||
| Autoantibodies | Antinuclear antibodies | 11 (100) | |
| Anti-topoisomerase I | 4 (36.4) | ||
| Anti-centromere | 0 (0) |